Alcon Laboratories, Inc. (NYSE: ALC), the US‑based eye care company, announced that it has acquired Neurotech Pharmaceuticals, Inc., a developer of innovative cell therapies for chronic and neurodegenerative eye diseases, in a transaction valued at USD 550 million — adding ENCELTO (revakinagene taroretcel‑lwey), the first and only U.S. FDA‑approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), to Alcon’s retina portfolio.
Acquisition Snapshot
| Item | Detail |
|---|---|
| Acquirer | Alcon Laboratories, Inc. (NYSE: ALC) |
| Target | Neurotech Pharmaceuticals, Inc. – cell therapies for chronic and neurodegenerative eye diseases |
| Consideration | USD 550 million upfront acquisition payment |
| Contingent Payments | Additional payments may be required, including upon achievement of commercial milestones |
| Lead Asset | ENCELTO (revakinagene taroretcel‑lwey) – FDA‑approved MacTel Type 2 therapy |
| Financial Impact | Expected modestly accretive to net sales growth and slightly dilutive to core diluted EPS in 2027; accretive thereafter |
| Announcement Date | 20 Oct 2026 |
Product Profile – ENCELTO (revakinagene taroretcel‑lwey)
- Indication: Treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel) — the first and only FDA‑approved therapy for the condition.
- Disease Context: MacTel is a rare, progressive retinal disease that leads to irreversible central vision loss and, historically, had no approved treatment options.
- Modality: An encapsulated cell therapy intended for surgical intravitreal implantation — a device‑based cell therapy architecture in which encapsulated therapeutic cells are implanted into the vitreous cavity.
- Regulatory History: FDA‑approved under a Biologics License Application (BLA) in March 2025, with priority review status and Orphan Drug designation.
- Commercial Availability: Currently marketed in the U.S. only, leaving potential ex‑US expansion as an additional growth lever under Alcon ownership.
Market Impact & Outlook
- Retina Portfolio Expansion: The acquisition broadens Alcon’s retina franchise beyond surgical and pharmaceutical offerings into advanced cell therapy, one of the most innovative modalities in ophthalmology.
- First‑Mover Franchise: With ENCELTO the only approved therapy in MacTel, Alcon acquires a monopoly‑positioned orphan asset in a rare retinal disease with a historically untreated patient population.
- Platform Value: Neurotech’s encapsulated cell therapy platform targets chronic and neurodegenerative eye diseases, offering Alcon pipeline optionality beyond the lead approved product.
- Financial Profile: Alcon expects the transaction to be modestly accretive to net sales growth, slightly dilutive to core diluted EPS in 2027, and accretive thereafter — with additional value tied to commercial milestone contingent payments.
- Disclosures: Closing date, ex‑US launch plans, revenue contribution, and milestone payment amounts were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the integration of Neurotech Pharmaceuticals, commercialization of ENCELTO, milestone achievement, and the transaction’s financial impact on Alcon’s net sales growth and core diluted EPS. Actual results may differ materially due to risks including integration execution, market adoption in a rare disease population, regulatory developments, and competitive dynamics. Acquisition completion expectations and accretion/dilution projections are subject to change.-Fineline Info & Tech
